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Aims: To examine which preoperative factors including urodynamic evaluations 
and operative procedure could predict the incontinence status after 
robot-assisted radical prostatectomy (RARP) in this study. 
Materials and Methods: Univariate and multivariate logistic regression 
analyses of preoperative such as age, body mass index, prostate-specific 
antigen level before biopsy, prostate size before surgery, membranous urethral 
length measured using magnetic resonance imaging (MRI), bladder compliance 
and maximum urethral closure pressure (MUCP) measured by the urodynamic 
study (UDS), and nerve-sparing (NS) status predicting 24-h pad test > 2 g/day at 
1 year after RARP were examined in 111 patients enrolled in this study.  
Results: The number of patients with incontinence at 1 year after RARP was 39 
(35.1%). The only predictive factor for urinary continence was NS grades. To 
investigate the contribution of NS to urinary continence, the UDS was conducted 
in 84 patients who had undergone the procedure three times, before, 
immediately after, and 1 year after RARP. Chronological UDS revealed that 
recovery patterns of storage and voiding functions were the same among 
non-NS, unilateral-NS, and bilateral-NS groups, and the higher degree of NS 
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contributed to a lesser decreases in MUCP and longer functional urethral length 
(FUL) after RARP 
Conclusion: Preoperative factors, including the results of UDS, could not 
predict continence 1 year after RARP. The NS procedure contributed to the 
continence status. NS favorably affected MUCP and FUL; however, it did not 












Radical prostatectomy (RP) is a standard treatment for localized prostate 
cancer. One of the most inconvenient complications influencing the quality of life 
after RP is urinary incontinence.1 Robot-assisted radical prostatectomy (RARP) 
is reported to offer a better outcome with regard to post-prostatectomy 
incontinence (PPI) than the conventional methods.2 However, not all patients 
achieved the continence status after RARP. 
Predictive factors such as patient age,3,4 body mass index (BMI)5 and 
prostate size,6,7 have been reported to date. In addition, the membranous 
urethral length (MUL) measured using magnetic resonance imaging (MRI) is 
reported to be a predictive factor for PPI.8 In some report, detrusor overactivity9 
and low maximum urethral closure pressure (MUCP)9,10 evaluated by the 
urodynamic study (UDS) before surgery have been shown to adversely affect 
the continence status after RP. In terms of the operative technique, a 
nerve-sparing (NS) procedure has been reported to contribute not only to the 
recovery of urinary continence immediately after RP, but also to the continence 
status for a long time after RP. 11,12 
To evaluate the continence status, some validated questionnaires had 
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been invented. The International Consultation on Incontinence 
Questionnaire-Short Form (ICIQ-SF) is one of these and has been used for the 
evaluation of PPI.13 Many reports have adopted pad use as a definition of the 
continence status because of its simplicity. However, this definition offers 
subjective evaluation and possibly little objectivity, therefore, its evaluation is 
possibly ambiguous.14 The International Continence Society (ICS) has 
recommended the pad weight test for the evaluation of PPI15, and a 24-hr pad 
test seems to be the most accurate.14,16 
In this study, using the data of RARP performed in our institution, PPI was 
evaluated using the 24-hr pad test. We examined which preoperative factors 
including urodynamic evaluations, and operative procedures, could predict the 
PPI status. Using chronological urodynamic data, we also examined how 
predictive factors could contribute to the continence status. 
 
MATERIALS AND METHODS 
Following institutional ethics committee approval, patients with clinically 
localized prostatic cancer undergoing RARP by a surgeon who had performed 
RARP in more than 100 cases at the Kanazawa University Hospital between 
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November 2011 and July 2013 were included in this study. All patients provided 
written informed consent. They were taught pelvic floor muscle exercises; 
patients began these exercises 1 month preoperatively and continued them 
postoperatively until urinary continence was recovered. The estimated prostate 
size was measured using transrectal ultrasound few days before surgery. MUL 
was measured on the coronal images of MRI as the distance from prostatic apex 
to the entry of the urethra into the penile bulb.8  
RARP was performed via a transperitoneal approach. Transection of the 
prostate began from the anterior surface of the bladder neck; thereafter, an 
incision was made between the bladder and the prostate toward the retrotrigonal 
layer.17 NS procedures, such as inter- or intrafascial dissection, were performed 
depending on the cancer status. 12 When a non-NS procedure was performed, 
the neurovascular bundle was resected. The dorsal venous complex was 
athermally divided without ligation and sutured for hemostasis after division. 
Double-layered posterior reconstruction was performed before urethrovesical 
anastomosis. Urethrovesical anastomosis was performed using a running suture 
with a double-armed 3-0 monocryl. The urethral catheter was removed 6–7 days 
postoperatively by cystographic evaluation. Cystometry (CM), pressure-flow 
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study (PFS), urethral pressure profilometry (UPP), and abdominal leak point 
pressure (ALPP) were performed 1–2 days preoperatively (pre), 3–4 days after 
catheter removal (post), and approximately 1 year postoperatively considered as 
the stable continence period (stable). To obtain the information of the 
incontinence status, 24-h pad tests were performed. A platform scale was 
provided to the patients, and they were asked to weigh the pad before and after 
use. The increase in weight of the pad over 24 h was measured for 3 
consecutive days approximately 1 year after RARP. The continence status was 
defined as not exceeding 2 g/day pad weight gain at mean weight of 3 
consecutive days. A questionnaire for daily pad use and the ICIQ-SF were 
administered at the same time.18 
UDSs were performed according to the Good Urodynamic Practice 
Guidelines of the ICS.19 CM was performed using a 6-F double-lumen Nelaton 
transurethral catheter with normal saline solution (37°C) at a filling rate of 50 
ml/min and abdominal pressure was monitored using a 10-F intrarectal balloon 
catheter. The maximum cystometric capacity (MCC), and bladder compliance 
(BC) were measured by the filling CM. After the patients were asked to void at 
capacity, the maximum flow rate (Qmax) and detrusor pressure at the maximum 
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flow rate (PdetQmax) were measured. The transurethral catheter was removed 
at 60 mm/min using an electronic puller with a perfusion rate of 2 mL/min to 
measure static UPP. MUCP and functional urethral length (FUL) were measured 
by UPP. ALPP was measured at a volume of 150 mL (or half bladder capacity if 
the capacity was ≥ 300 mL) using a rectal monitor with urethral catheter removal. 
The cough or valsalva maneuver was performed at least 5 times, and ALPP was 
defined as the lowest pressure inducing visible incontinence. If no incontinence 
was observed with an abdominal pressure of >100 cmH2O, ALPP was defined 
as “negative.” In this analysis, the maximum abdominal pressure in all cases 
without urine leakage in the ALPP test was measured over 100 cmH2O.20 These 
measured values were used in calculations as ALPP. UDSs and analyses were 
performed using the Solar Silver digital urodynamic apparatus (Medical 
Measurement Systems, Enschede, The Netherlands).  
Categorical variables used to calculate the incidence and percentage of 
each factor and continuous variables were summarized by mean ± standard 
deviation (SD). Unpaired t test was used for categorical variables of 2 levels, and 
analysis of variance (ANOVA) was used for categorical variables of more than 2 
levels. Tukey’s honest significant difference test was used for multiple 
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comparisons/post hoc tests. Univariate and multivariate logistic regression 
analyses were used to evaluate the variables significantly related to urinary 
continence after RARP. All data analyses were performed using SPSS for 




In total, 111 patients who underwent preoperative MRI and UDS 
preoperatively and a 24-hr pad test at the stable period after RARP were 
enrolled. No patient used pads or collecting devices before RARP. No patients 
had complications >grade III of RARP according to Clavian Classification. 
Univariate and multivariate logistic regression analyses of preoperative factors 
such as age, BMI, prostate-specific antigen (PSA) level before biopsy, prostate 
size before surgery, MUL measured using MRI, BC measured by CM, MUCP 
measured by UPP, and the NS status predicting 24-h pad test > 2 g/day at 1 
year after RARP were examined (TABLE I). All patients with a 24-h pad test < 2 
g/day were those with no daily pad use or security pad use per day. The 
number of patients with a 24-h pad test > 2 g/day at the stable period was 39 
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(35.1%). Univariate analysis showed that the NS procedure was the only 
predictive factor for urinary continence at the stable period. Multivariate 
analysis with the NS status and bladder compliance, as representatives of 
bladder functions, and MUCP, as a representative of urethral function, also 
showed that the NS procedure was the only predictive factor for urinary 
continence at the stable period. To investigate chronological changes in lower 
urinary functions with or without NS, the results of UDS of 84 patients who had 
previously undergone UDS three times at the pre, post, and stable periods were 
examined. Non-NS procedures were performed in 33 patients (39.3%), 
unilateral NS in 36 (42.8%), and bilateral NS in 15 (17.9%). The demographics 
are shown in TABLE II. The D’Amico risk group and urinary continence status 
were statistically different among the groups. The results of CM and UDS are 
shown in Fig 1. There was no statistical difference among the groups. The 
results of UPP and ALPP are shown in Fig. 2. MUCP of non-NS at post-RARP 
decreased to 39.2% compared with MUCP at pre-RARP, MUCP of 
unilateral-NS at post-RARP decreased to 42.0%, and MUCP of bilateral-NS at 
post-RARP decreased to 53.6%. Subsequently, MUCP of non-NS at 
stable-RARP recovered to 72.3% compared with MUCP at pre-RARP, MUCP of 
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unilateral-NS recovered to 79.7%, and MUCP of bilateral-NS recovered to 
93.3%. The decline in MUCP after RARP became mild with high-grade NS (Fig. 
2 A). FULs with higher NS grades tended to be longer, and there was a 
statistical difference between non-NS and bilateral-NS at post-RARP (Fig. 2B). 
ALPPs with higher NS grades tended to be higher; however, there was no 
statistical difference among the groups (Fig. 2C). 
 
DISCUSSION 
Daily pad use, interviews or questionnaires for the incontinence status, and 
a pad test were usually used to evaluate PPI. However, there is no consensus 
on how to appropriately evaluate PPI. Little correlation between the number of 
pads used and the severity of urinary incontinence has been reported14, and 
older patients have a higher volume of urine leakage per pad than the younger 
generation.16 Therefore, the 24-h pad test which strongly correlates with 
subjective urinary incontinence18 and seems to be the most reliable test was 
used for evaluating PPI in this study.15 There is no consensus on the definition of 
pad weight gain as urinary continence in the 24-h pad test. All patients with a 
24-h pad test < 2 g/day answered “no urine leakage” by questionnaires 
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simultaneously completed in this study, therefore, the definition of urinary 
continence as a 24-h pad test < 2 g/day was adopted.21 In the present study of 
the preoperative factors predicting PPI as reported previously, such as age3,4, 
BMI5, prostate size6,7, MUL measured by MRI8,BC evaluated by CM, MUCP 
evaluated by UPP9,10, and PSA, preoperative MUCP tended to affect urinary 
continence at the stable period. However, there were no statistically significant 
predictive factors in this study. The results indicated that there were no 
preoperative predictive factors for PPI (TABLE I), as reported previously.22 In the 
previous reports, evaluations of PPI were mostly determined by subjective 
answers through interviews or questionnaires3,5,7 or daily pad use.4,6,8-10. There 
are few reports using a 24-h pad test for evaluating PPI.22 One of the reasons for 
the difference in results from previous studies may be the definition of PPI. Some 
reports have shown that the NS procedure favorably affected RP both 
immediately after and a long time after RP.11,12 In agreement with that reported 
previously,12 in the present study, the degree of preservation of neurovascular 
bundles affected urinary continence at the stable period after RARP.  
Chronological UDS were performed to evaluate each lower urinary tract 
elements affected by the NS procedure. Among the non-NS, unilateral-NS and 
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bilateral-NS groups, there were no statistical differences in preoperative factors 
such as age, BMI, PSA before biopsy, neoadjuvant androgen deprivation 
therapy (NADT), prostate size before surgery, and MUL measured by MRI; 
however, there was a statistical difference in the D’Amino risk group criteria 
because the indications of NS were determined by the cancer status (TABLE II). 
From the results of UDS, bladder storage function evaluated by MCC and BC 
deteriorated immediately after RARP; however, it recovered to the preoperative 
level at the stable period after RARP, and there was no statistical difference by 
the NS status (Fig. 1A, B). The results of PdetQmax showed low-pressure 
urination immediately after RARP because of the removal of the prostate. 
However, the maximum flow rate did not improve immediately after RARP but at 
the stable period after RARP. This shows the possibility that the detrusor 
functions need time to recover. Recovery patterns of voiding functions were the 
same among different NS groups (Fig. 1C, D). MUCP evaluated by UPP 
decreased immediately after RARP and recovered at the stable period; however, 
it did not reach preoperative levels. The higher degree of NS contributed to a 
lesser decreases in MUCP (Fig. 2A). FUL decreased after RP because of the 
removal of the prostate, and FUL after RP was only measured by the length of 
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membranous urethra. MULs measured by MRI before RP were not statistically 
different among different NS groups (TABLE II). The higher degree of NS 
contributed to significantly longer FUL immediately after RARP, and FULs 
tended to be longer. However, these levels were statistically insignificant among 
different NS groups at the stable period (Fig.2B). ALPP showed no urine leakage 
in the test before RARP, and no significant difference in the number of patients 
with a urine leak in the test after RARP among different NS groups (Fig. 2C). The 
measured values of ALPP decreased immediately after RARP, and recovered 
almost to the same preoperative level at stable period after RARP. The results 
evaluated by UDS in this study showed that the NS procedure possibly 
contributed to maintain static urethral closure pressure after RP by preventing a 
decrease in MUCP and FUL. Even if the NS procedure is conducted, the nerves 
are impaired by the operative procedure and require several months to recover 
their function. Anatomically, multiple connective tissue layers, including nerves 
and vessels, surround the prostatic capsule. In the nerve-sparing procedure, we 
performed prostatectomy, ensuring least disturbance to the surrounding tissues. 
Therefore, the structures near the urethral sphincter are thought to be 
well-preserved more in NS than in non-NS. These preserved structures may 
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contribute to sphincter function immediately after surgery. ALPP was used to 
investigate stress urinary incontinence (SUI) and did not show significant 
differences among the different NS groups; therefore, NS may not contribute to 
prevent SUI, such as bladder neck hypermobility, after RP. Bladder functions 
recovered to preoperative levels at the stable period after RARP in this study. A 
previous report on open RP series evaluating changing bladder function after RP 
using UDS showed the deterioration in bladder function at the early period after 
RP, and little recovery of bladder function was observed after a long period 
following RP.23 The anterior approach performed in RARP, for transection 
between bladder and prostate contributes to minimize the invasiveness of the 
bladder neck. Therefore, compared with open RP, the lesser invasiveness of this 
procedure seems to affect the improvement of bladder function at the stable 
period after RARP.24  
This study had several limitations. The sample size of patients in this 
study was not large enough to draw definitive conclusions. Pathological 
examinations to evaluate resected periprostatic nerves were not performed; 
therefore, pathological evidences of NS are not shown in this study. The urinary 
continence definition in this study was considered to be a 24-h pad test < 2 g/day 
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on the based of our data from questionnaires and a previous study.21 The 24-h 
pad test is possibly more objective and accurate than the subjective 
questionnaires and a daily pad use; however, there is no consensus on the 
cut-off levels for pad weight gain after 24-h pad use to define the continence 
status. If no incontinence was observed with an abdominal pressure >100 
cmH2O, the ALPP was defined as “negative.” In this analysis, the maximum 
abdominal pressure in all cases without urine leakage in the ALPP test was 
measured over 100 cmH2O.20 These measured values were used in calculations 
as ALPP. However, there is no standard method for evaluating method of ALPP 
which we used in this study. In this study, the period of 1year after RARP was 
defined as stable period; however, changes in the function of the lower urinary 
tract lasted longer than 1 year after RARP and the evaluations for longer time 
period were not performed.  
 
CONCLUSIONS 
Preoperative factors including the results of UDS could not predict the 
continence status at the stable period after RARP in this study. The NS 
procedure contributed to the continence status at the stable period after RARP. 
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UDS revealed that NS favorably affected MUCP and FUL after RARP and this is 
thought to be one of the mechanisms of NS contribution to the continence status. 
Chronological UDS in this study revealed that the storage functions recovered to 
the preoperative level at 1 year after RARP. In addition, the voiding function 
improved at 1 year after RARP compared with that before RARP, whereas NS 
did not affect the bladder functions after RARP.  
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Fig 1. Urodynamic evaluation at each time point in filling cystometry and 
pressure-flow study: (A) maximum cystometric capacity, (B) bladder compliance, 
(C) maximum flow rate, (D) detrusor pressure at maximum flow rate (PdetQmax). 
The numbers in the figure show mean ± SD of the urodynamic results at each 
time point. pre: before robot-assisted radical prostatectomy (RARP); post: 
immediately after RARP; stable: 1 year after RARP. 
 
Fig 2. Urodynamic evaluation at each time point in urethral pressure profile and 
abdominal leak point pressure test: (A) maximum urethral closure pressure, (B) 
functional urethral length, (C) abdominal leak point pressure. The numbers in the 
figure show mean ± SD of the urodynamic results at each time point. pre: before 
robot-assisted radical prostatectomy (RARP); post: immediately after RARP; 
stable: 1 year after RARP. (C) The numbers above the figure show the number 
(%) of positive abdominal leak point pressure. 
 
 
TABLE I. Univariate and multivariate logistic regression analyses of preoperative factors and nerve sparing 
status predicting 24-hr pad test > 2gr/day at stable period (n = 111) 




Multivariate   
  OR (95%CI) p value   OR (95%CI) p value 
Age 1.008 (0.936-1.085) 0.834 
   
Body mass index 0.922 (0.799-1.064) 0.265 
   
PSA 0.997 (0.907-1.095) 0.942 
   
Prostate size 1.001 (0.961-1.042) 0.973 
   
MUL by MRI 0.972 (0.831-1.138) 0.725 
   
Bladder compliance 1.002 (0.975-1.030) 0.971 
 
1.003 (0.975-1.033) 0.816 
MUCP 0.990 (0.974-1.006) 0.115 
 
0.988 (0.972-1.004) 0.144 




   unilateral (n = 53) 0.375 (0.158-0.892) 0.027 
 
0.364 (0.151-0.878) 0.024 
   bilateral (n = 19) 0.253 (0.071-0.901) 0.034   0.228 (0.063-0.827) 0.025 
Number of patients with 24 h pad test > 2gr./day at stable period = 39 (35.1%) 
 
OR, odds ratio; CI, confidence interval; PSA, prostate specific antigen; MUL, membranous urethral length;  
MUCP, Maximum urethral closure pressure; MRI, magnetic resonance imaging; NS, nerve sparing 
 
TABLE II. Demographics of the study population receiving chronological UDS 
 
      
    
Mean (±SD) or n (%) 
      
 
ALL non NS unilateral NS bilateral NS p-value 
  n = 84  n = 33  n = 36 n = 15   
Age, y 65.0 (±5.4) 65.8 (±5.0) 64.8 （±6.0） 63.8 (±5.1) 0.518 
Body mass index, kg/m2 23.8 (±2.6) 23.7 （±2.2） 23.8 （±3.1） 23.9 （±2.1） 0.958 
PSA, ng/ml 8.2 (±4.4) 8.1（±3.6） 8.8（±5.5） 7.0 （±3.1） 0.38 
      Biopsy Gleason score 
    
0.068 
 6 31 (37%) 12 (36%) 9 (25%) 10 (67%) 
 
 7 43 (51%) 17 (52%) 21 (58%) 5 (33%) 
 
 8-10 10 (12%) 4 (12%) 6 (17%) 0 (0%) 
 
Clinical T stage 
    
0.068 
 1 28 (33%) 12 (36%) 10 (28%) 6 (40%) 
 
 2 49 (59%) 15 (46%) 25 (70%) 9 (60%) 
 
 3 7 (8%) 6 (18%) 1 (3%) 0 (0%) 
 
D'Amico risk group 
    
0.021 
 Low 26 (31%) 9 (27%) 8 (22%) 9 (60%) 
 
 Intermediate 33 (39%) 10 (30%) 18 (50%) 5 (33%) 
 
 High 25 (30%) 14 (42%) 10 (28%) 1 (7%) 
 
NADT 
    
0.385 
 No 67 (80%) 24 (73%) 31 (86%) 12 (80%) 
 
 Yes 17 (20%) 9 (27%) 5 (29%) 3 (20%) 
 
      Prostate size, ml 40.4 (±9.0) 39.9（±8.9） 39.4 （±9.6） 43.8 (±7.2) 0.267 
MUL, mm 13.6 (±2.4) 13.9（±2.4） 13.9 （±2.2） 14.7 （±3.1） 0.382 
      24-h pad test > 2g/day 
    
0.023 
 No 53 (63%) 15 (46%) 26 (72%) 12 (80%) 
 
 Yes 31 (37%) 18 (55%) 10 (28%) 3 (18%) 
 
24-h pad weight, g 
     
  < 2 53 (63%) 15 (46%) 26 (72%) 12 (80%) 
 
  2 <  < 10 17 (20%) 8 (24%) 7 (19%) 2 (13%) 
 
 10 <  < 50 11 (13%) 7 (21%) 3 (9%) 1 (7%) 
 
 50 < 3 (4%) 3 (9%) 0 (0%) 0 (0%)   
SD, standard deviation; NS, nerve sparing; PSA, prostate-spacific antigen; NADT, neoadjuvant 
androgen deprivation therapy; MUL, membranous urethral length 
 


